Great efficacy of sulfachloropyrazine-sodium against acute murine toxoplasmosis

Asian Pacific Journal of Tropical Biomedicine

Volumn 2, Issue 1, 2012, Pages 70-75

  Zeng, Yan Bo ^a   Zhu, Shun Hai ^a   Dong, Hui ^a   Han, Hong Yu ^a   Jiang, Lian Lian ^a   Wang, Quan ^a   Cheng, Jun ^a   Zhao, Qi Ping ^a   Ma, Wei Jiao ^a   Huang, Bing ^a  

^a INSTITUTE OF EDIBLE FUNGI   (China)

Author keywords

Efficacy; Murine; Sulfachloropyrazine sodium; Sulfonamides; Therapeutic effect; Therapy; Toxoplasma gondii; Toxoplasmosis

Indexed keywords

ANTIPROTOZOAL AGENT; SULFACHLOROPYRAZINE SODIUM; SULFACHLORPYRIDAZINE SODIUM; SULFADIAZINE; SULFADIMIDINE; SULFAMATHOXYDIAZINE SODIUM; SULFAMATHOXYPYRIDAZINE SODIUM; SULFONAMIDE; TRIMETHOPRIM; UNCLASSIFIED DRUG; PROTOZOAL DNA; SULFACHLORPYRAZINE; SULFANILAMIDE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROTOZOAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; EVENING DOSAGE; FEMALE; MORNING DOSAGE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PARASITE IDENTIFICATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SURVIVAL TIME; TOXOPLASMA GONDII; TOXOPLASMOSIS; TROPHOZOITE; ANIMAL; DISEASE MODEL; DRUG EFFECTS; GENETICS; HEART; ISOLATION AND PURIFICATION; KIDNEY; ORAL DRUG ADMINISTRATION; PARASITOLOGY; SURVIVAL; TOXOPLASMA; TREATMENT OUTCOME;

ANIMALIA; MURINAE; MUS; TOXOPLASMA GONDII;

ADMINISTRATION, ORAL; ANIMALS; ANTIPROTOZOAL AGENTS; DISEASE MODELS, ANIMAL; DNA, PROTOZOAN; FEMALE; HEART; KIDNEY; MICE; POLYMERASE CHAIN REACTION; SULFANILAMIDES; SURVIVAL ANALYSIS; TOXOPLASMA; TOXOPLASMOSIS; TREATMENT OUTCOME;

EID: 84863249750     PISSN: 22211691     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2221-1691(11)60193-7     Document Type: Article

References (28)

1. Lorraine JB, John DA, Posner GH, Yolken R. In vitro inhibition of Toxoplasma gondii by four new derivatives of artemisinin. Antimicrob Agents Chemother 2006; 50: 4206-4208.
2. Valentini P, Annunziata ML, Angelone DF, Masini L, Santis MD, Testa A, et al. Role of spiramycin/cotrimoxazole association in the mother-to-child transmission of toxoplas- mosis infection in pregnancy. Eur J Clin Microbiol Infect Dis 2009; 28: 297-300.
3. Kellogg JS, James JM. Development of a PCR-enzyme immunoassay oligoprobe detection method for Toxoplasma gondii oocysts, incorporating PCR controls. Appl Environ Microbiol 2003; 69: 5819-5825.
4. Dunay IR, Heimesaat MM, Bushrab FN, Müller R, Stocker HH, Arasteh K, et al. Atovaquone maintenance therapy prevents reactivation of Toxoplasmic encephalitis in a murine model of reactivated toxoplasmosis. Antimicrob Agents Chemother 2004; 48: 4848-4854.
5. Lass A, Pietkiewicz H, Modzelewska E, Dumètre A, Szostakowska B, Myjak P. Detection of Toxoplasma gondii oocysts in environmental soil samples using molecular methods. Eur J Clin Microbiol Infect Dis 2009; 28: 599-605.
6. Dubey JP, Jones JL. Toxoplasma gondii infection in humans and animals in the United States. Int J Parasitol 2008; 38: 1257-1278.
7. Jones JL, Deanna KM, Kolby SL, Wilson M. Toxoplasma gondii infection in the United States, 1999-2004, decline from the prior decade. Am J Trop Med Hyg 2007; 77: 405-410.
8. Coordinating Office of the National Survey on the Important Human Parasitic Diseases. A national survey on current status of the important parasitic diseases in human population. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 2005; 23: 332-340.
9. Dubey JP, Shen SK. Rat model of congenital toxoplasmosis. Infect Immun 1991; 59: 3301-3302.
10. Chio LC, Bolyard LA, Nasr M, Queener SF. Identification of a class of sulfonamides highly active against dihydropteroate synthase from Toxoplasma gondii, Pneumocystis carinii, and Mycobacterium avium. Antimicrob Agents Chemother 1996; 40: 727-733.
11. Allegra CJ, Boarman D, Kovacs JA, Morrison P, Beaver J, Chabner BA, et al. Interaction of sulfonamide and sulfone compounds with Toxoplasma gondii dihydropteroate synthase. J Clin Invest 1990; 85: 371-379.
12. Araujo FG, Huskinson J, Remington JS. Remarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondii. Antimicrob Agents Chemother 1991; 35: 293-299.
13. Kovacs JA, Masur H. Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection. N Engl J Med 2000; 342: 1416-1429.
14. Khan AA, Slifer TR, Araujo FG, Remington JS. Activity of gatifloxacin alone or in combination with pyrimethamine or gamma interferon against Toxoplasma gondii. Antimicrob Agents Chemother 2001; 45: 48-51.
15. Romand S, Pudney M, Derouin F. In vitro and in vivo activities of the hydroxynaphthoq- uinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii. Antimicrob Agents Chemother 1993; 37: 2371-2378.
16. Katlama C, Wit SD, O'Doherty E, Glabeke MV, Clumeck N. Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS. Clin Infect Dis 1996; 22: 268-275.
17. Baggish AL, Hill DR. Antiparasitic agent atovaquone. Antimicrob Agents Chemother 2002; 46: 1163-1173.
18. Haberkorn A. Chemotherapy of human and animal coccidioses: state and perspectives. Parasitol Res 1996; 82: 193-199.
19. Xiao SH, Keiser J, Jian X, Tanner M, Morson G, Utzinger J. Effect of single-dose oral artemether and tribendimidine on the tegument of adult Clonorchis sinensis in rats. Parasitol Res 2009; 104: 533-541.
20. Zhou P, Chen N, Zhang RL, Lin RQ, Zhu XQ. Food-borne parasitic zoonoses in China: perspective for control. Trends Parasitol 2008; 24: 190-196.
21. Wess LM, Kim K. Toxoplasma gondii: the model apicomplexanperspectives and methords. London: Academic Press, Elsevier; 2007, p. 185-206.
22. Liguoro MD, Fioretto B, Poltronieri C, Gallina G. The toxicity of sulfamethazine to Daphnia magna and its additivity to other veterinary sulfonamides and trimethoprim. Chemosphere 2009; 75: 1519-1524.
23. Derouin F, Hayat MS. Anti-toxoplasma activities of antiretroviral drugs and interactions with pyrimethamine and sulfadiazine in vitro. Antimicrob Agents Chemother 2000; 44: 2575-2577.
24. Masur H, Kaplan JE, Holmes KK. Guidelines for preventing opportunistic infections among HIV-infected persons-2002. Ann Intern Med 2002; 137: 435-477.
25. Meneceur P, Bouldouyre MA, Aubert D, Villena I, Menotti J, Sauvage V, et al. In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone. Antimicrob Agents Chemother 2008; 52: 1269-1277.
26. Fajer-Avila EJ, Morales-Covarrubias MS, Selene AR, Roque A, Pablo MB, Crisantema HG. Effectiveness of oral ElancobanTM and Avimix-STTM against Nematopsis (Apicomplexa: Porosporidae) gametocyts infecting the shrimp Litopenaeus vannamei. Aquaculture 2005; 244: 11-18.
27. Zhou P, Zhang H, Lin RQ, Zhang DL, Song HQ, Su CL, et al. Genetic characterization of Toxoplasma gondii isolates from China. Parasitol Int 2009; 58: 193-195.
28. Sibley LD, Dana GM, Su CL, Paul MR, Dan KH. Genetic approaches to studying virulence and pathogenesis in Toxoplasma gondii. Philos Trans R Soc Lond Biol Sci 2002; 357: 81-88.